CAR-T

#Artificial intelligence (AI) #CAR-T #Cell and gene therapy #Cell therapy

The future of cell therapy: AI has a role to play in breaking today’s barriers

Rafael Carazo Salas, CEO and Founder of CellVoyant, explores AI’s potential for cell therapies. AI is already making big strides in biotechnology and healthcare, from its remarkable accuracy in detecting breast cancer from mammograms, to AI platforms such as DeepMind’s AlphaFold revolutionising protein structure prediction. One of the most promising areas… Read More

#Exclusive Content

CAR-T cell attacking cancer
#Cancer therapy #CAR-T #Cell therapy #Cytokine Release Syndrome (CRS) #Cytokines #Poolbeg Pharma

CRS prevention: Taking the sting from CAR-T’s tail

Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More

#Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

#Adverse event #Cancer research #CAR-T #Cardio #CRISPR #CRISPR-Cas9 #Drug discovery #Gene editing #Imaging #Oncology #Screening

New podcast: Innovation enabled by new drug discovery technologies

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “CRISPR breakthroughs: New solutions for common diseases” and “Re-assessing the risks of… Read More

#News

Bristol Myers Squibb offices
#Bristol Myers Squibb #CAR-T #Cell therapy #Mergers and acquisitions

BMS buys CAR-T company 2seventy bio

Bristol Myers Squibb (BMS) is to acquire cell therapy developer 2seventy bio for approximately $286 million.  Under the terms of the agreement, BMS will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction.   2seventy bio’s Board… Read More

#Business & Investment #News

CAR-T in multiple myeloma
#CAR-T #Cell therapy #Interview #Kite Pharma #Oncology

CAR-T cell therapy: Overcoming critical infrastructure challenges 

DDW’s Diana Spencer speaks to Dan Tovar, Senior Director, Head of Cell Therapy ACE Midsize Markets, Medical Affairs at Kite Pharma, about the current landscape for cell therapies and what can be done to improve patient access.  DS: Kite has pioneered cell therapy, with Yescarta (axicabtagene ciloleucel) as one of… Read More

#Business & Investment #Cancer Research #Exclusive Content

CAR-T therapy
#CAR-T #Cell manufacturing #Cell therapy #Oncology

Bringing CAR-T cell production closer to patients

Dr Liping Yu, Vice President of Applications at Applied Cells, looks at barriers to access for CAR-T cell therapies. CAR-T cell therapies are increasingly being used to treat life-threatening conditions when other treatments have failed, particularly in oncology. Autologous CAR-T cancer therapies involve isolating T cells from a patient’s blood,… Read More

#Cancer Research #Exclusive Content

Cancer cell
#CAR-T #Cell therapy #Haematology #Interview #March Biosciences #Oncology

Pushing past the limitations of CAR-T therapies

DDW Editor Reece Armstrong speaks to Sarah Hein, CEO and Co-founder of March Biosciences, about the company’s recent fundraising efforts and its development of CAR-T therapies addressing challenging blood cancers. RA: What are the limitations of current standard-of-care therapies for blood cancers? SH: There are many treatment options for the… Read More

#Exclusive Content

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

New DDW Highlights episode: 10 February 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Following World Cancer Day on 4 February, the news round-up this week focuses on… Read More

#News

#Cancer therapeutics #Cancer vaccine #CAR-T #Oncology #Radiopharmaceuticals

This week in drug discovery (3-7 February) 

News round-up for 3-7 February by DDW Senior Digital Content Editor Diana Spencer. Following World Cancer Day on 4 February, the news round-up this week focuses on new approaches to the treatment of cancer, including radiopharmaceuticals, programmable cell depletion and preventative vaccines. The top stories:… Read More

#News

CAR-T therapy
#Allogene Therapeutics #Autoimmune disease #CAR-T #Cell therapy #FDA #Phase I trial

Allogeneic CAR-T therapy gets go-ahead for rheumatology trial

Allogene Therapeutics has been given the green light from the US Food and Drug Administration (FDA) for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR-T product.  The Phase I RESOLUTION basket trial will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including… Read More

#Cancer Research #News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #FDA #Haematology #March Biosciences #Oncology

FDA Orphan Drug Designation for CD5 CAR-T cell therapy

The US Food and Drug Administration (FDA) has granted orphan drug designation to MB-105, March Biosciences’ CD5-targeted CAR-T cell therapy for the treatment of relapsed/refractory CD5-positive T-cell lymphoma (TCL).  MB-105 is in development as a treatment for TCL, T-cell acute lymphoblastic leukaemia (T-ALL), chronic lymphocytic leukaemia (CLL), and mantle cell… Read More

#News #Regulatory

#Autoimmune disease #CAR-T #Cell and gene therapy #Cell therapy

Expanding access to cell therapies for autoimmune conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both… Read More

#Exclusive Content

CAR-T in multiple myeloma
#CAR-T #Cell therapy #EsoBiotec #In vivo #Myeloma #Pregene Biopharma

In vivo BCMA CAR-T candidate shows promise in first human trial

EsoBiotec and Pregene Biopharma have dosed the first patient in an investigator-initiated clinical trial in China of ESO-T01 for relapsed/refractory multiple myeloma.   ESO-T01 is an immune shielded lentiviral vector that reprograms T lymphocytes in vivo into highly effective BCMA CAR-T cells.  The clinical… Read More

#Cancer Research #News

Gene therapy concept
#Blood cancer #CAR-T #Cell therapy #Regenerative Medicine #Stem cells #Tune Therapeutics

Unlocking the future of medicine with cell therapy

Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More

#Cancer Research #Exclusive Content #Opinion

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights episode: 16 December 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a big week for cell and gene therapies… Read More

#News